Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ALT | Common Stock, par value $0.0001 | Options Exercise | $57.6K | +30K | +259.85% | $1.92 | 41.5K | Feb 28, 2022 | Direct | |
transaction | ALT | Common Stock, par value $0.0001 | Sale | -$226K | -30K | -72.21% | $7.52 | 11.5K | Feb 28, 2022 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ALT | Stock Options (option to buy) | Options Exercise | $0 | -30K | -48.86% | $0.00 | 31.4K | Feb 28, 2022 | Common Stock, par value $0.0001 | 30K | $1.92 | Direct | F3 |
Id | Content |
---|---|
F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.70, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
F3 | Twenty-five percent of the shares underlying the option became vested and exercisable on January 2, 2021 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 2, 2021, subject to the reporting person's continued service through the applicable vesting date. |